Teva Pharma (TEVA)
36.36
-0.26 (0.71%)
Upcoming Events
Latest Headlines
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
September 4, 2026 11:30 AM - Globe NewsWire
Teva Pharma (TEVA) PT Raised to $48 at UBS
September 4, 2026 5:46 AM - StreetInsider
Form 8-K TEVA PHARMACEUTICAL INDU For: Sep 03
September 3, 2026 4:13 PM - SEC Filing
Form 8-K TEVA PHARMACEUTICAL INDU For: Aug 31
September 3, 2026 4:06 PM - SEC Filing
Teva's TEV '408 meets primary endpoint in celiac disease trial
September 2, 2026 7:08 AM - StreetInsider
Teva in talks with Trump administration on Medicaid drug pricing
August 31, 2026 4:08 PM - StreetInsider
Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
August 31, 2026 4:06 PM - Globe NewsWire
Teva bids $57.5M for BioXcel agitation drug in bankruptcy sale
August 28, 2026 6:17 AM - StreetInsider
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
August 28, 2026 6:17 AM - Globe NewsWire
Immuneering touts Phase 3 trial as FDA clears new pancreatic cancer drug
August 26, 2026 5:16 PM - StreetInsider
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
August 26, 2026 5:16 PM - Globe NewsWire
Form 4 TEVA PHARMACEUTICAL INDU For: Aug 21 Filed by: Weiss Amir
August 25, 2026 4:05 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Aug 21 Filed by: Satchi-Fainaro Ronit
August 25, 2026 4:03 PM - SEC Filing
Aurinia settles patent dispute with Teva over generic voclosporin
August 19, 2026 4:05 PM - StreetInsider
Form 4 TEVA PHARMACEUTICAL INDU For: Aug 17 Filed by: Lippman Evan
August 19, 2026 4:01 PM - SEC Filing
FDA accepts Teva's drug application for Tourette syndrome therapy in children
August 19, 2026 8:56 AM - StreetInsider
Form 144 TEVA PHARMACEUTICAL INDU Filed by: Lippman Evan
August 17, 2026 4:00 PM - SEC Filing
Teva Pharma (TEVA) PT Raised to $42 at Barclays
August 12, 2026 5:26 AM - StreetInsider
Form 4 TEVA PHARMACEUTICAL INDU For: Aug 05 Filed by: Zaks Tal Zvi
August 10, 2026 6:08 AM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Aug 03 Filed by: Jover Placid
August 5, 2026 4:05 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Aug 03 Filed by: Hughes Eric A
August 5, 2026 4:03 PM - SEC Filing
Form 10-Q Immuneering Corp For: Jun 30
August 5, 2026 7:57 AM - SEC Filing
Form 8-K Immuneering Corp For: Aug 05
August 5, 2026 7:41 AM - SEC Filing
Form 144 TEVA PHARMACEUTICAL INDU Filed by: Hughes Eric A
August 3, 2026 4:02 PM - SEC Filing
Form 144 TEVA PHARMACEUTICAL INDU Filed by: Jover Placid
August 3, 2026 4:00 PM - SEC Filing
Form F-6 POS TEVA PHARMACEUTICAL INDU Filed by: Citibank,N.A./ADR
July 29, 2026 4:16 PM - SEC Filing
Form 10-Q TEVA PHARMACEUTICAL INDU For: Jun 30
July 29, 2026 4:02 PM - SEC Filing
Teva seeks clarity on Trump drug tariff plans, CEO says
July 29, 2026 10:21 AM - StreetInsider
UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
July 29, 2026 7:42 AM - BizWire
Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
July 29, 2026 7:24 AM - BizWire
Teva Pharma (TEVA) Misses Q2 EPS by 60c ; Offers Guidance
July 29, 2026 7:20 AM - StreetInsider
Form 8-K TEVA PHARMACEUTICAL INDU For: Jul 29
July 29, 2026 7:00 AM - SEC Filing
Form SCHEDULE 13G Immuneering Corp Filed by: BlackRock, Inc.
July 28, 2026 4:46 PM - SEC Filing
Teva Pharma (TEVA) PT Raised to $44 at Piper Sandler
July 28, 2026 7:14 AM - StreetInsider
Piper Sandler Reiterates Overweight Rating on Teva Pharma (TEVA)
July 20, 2026 8:40 AM - StreetInsider
Piper Sandler Reiterates Overweight Rating on Teva Pharma (TEVA)
July 20, 2026 8:38 AM - StreetInsider
Form 4 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew
July 17, 2026 4:29 PM - SEC Filing
Form 3 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew
July 16, 2026 4:11 PM - SEC Filing
Teva lawsuit against Eli Lilly over Forteo revived by appeals court
July 13, 2026 3:27 PM - StreetInsider
Teva to advance vitiligo antibody TEV-'408 into Phase 2b trials
July 7, 2026 7:36 AM - StreetInsider
UBS Reiterates Buy Rating on Teva Pharma (TEVA) as Pipeline Opportunities Broaden
June 26, 2026 9:35 AM - StreetInsider
Form 4 Immuneering Corp For: Jun 23 Filed by: Zeskind Benjamin J.
June 24, 2026 4:11 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 18 Filed by: Shields Matthew
June 22, 2026 4:01 PM - SEC Filing
Teva submits NDA for ecopipam to treat pediatric Tourette syndrome
June 18, 2026 4:58 PM - StreetInsider
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
June 18, 2026 4:56 PM - Globe NewsWire
Form 144 TEVA PHARMACEUTICAL INDU Filed by: Shields Matthew
June 18, 2026 4:15 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 15 Filed by: Hall Brett Matthew
June 16, 2026 4:15 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 11 Filed by: Kalif Eliyahu Sharon
June 16, 2026 8:28 AM - SEC Filing
Form 8-K Immuneering Corp For: Jun 11
June 15, 2026 4:12 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: Schall Thomas J.
June 11, 2026 5:38 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: HAUSMAN DIANA
June 11, 2026 5:33 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: CARPENTER ROBERT J
June 11, 2026 5:30 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: KEATING LAURIE
June 11, 2026 5:26 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: Feinberg Peter
June 11, 2026 5:23 PM - SEC Filing
Form 8-K Immuneering Corp For: Jun 11
June 11, 2026 5:16 PM - SEC Filing
Form 144 TEVA PHARMACEUTICAL INDU Filed by: Kalif Eliyahu Sharon
June 11, 2026 4:01 PM - SEC Filing
Immuneering doses first patient in phase 3 pancreatic cancer trial
June 11, 2026 7:30 AM - StreetInsider
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
June 11, 2026 7:30 AM - Globe NewsWire
Teva completes $700 million acquisition of Emalex Biosciences
June 10, 2026 12:03 PM - StreetInsider
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
June 10, 2026 12:03 PM - Globe NewsWire
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: BARER SOL J
June 8, 2026 4:07 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: Lichtenstein Chen
June 8, 2026 4:07 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: Crane Rosemary A
June 8, 2026 4:07 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: Elstein Amir
June 8, 2026 4:05 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: LIEBERMAN GERALD M
June 8, 2026 4:05 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: Nisen Perry
June 8, 2026 4:05 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: Satchi-Fainaro Ronit
June 8, 2026 4:03 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: Zaks Tal Zvi
June 8, 2026 4:03 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: MIGNONE ROBERTO
June 8, 2026 4:03 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: Francis Richard D
June 8, 2026 4:01 PM - SEC Filing
Full Article List
